You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
Dow
Johnson and Johnson
McKesson

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

Letermovir - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for letermovir and what is the scope of freedom to operate?

Letermovir is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Letermovir has eighty patent family members in forty-four countries.

One supplier is listed for this compound.

Summary for letermovir
International Patents:80
US Patents:3
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 28
Clinical Trials: 10
Patent Applications: 147
What excipients (inactive ingredients) are in letermovir?letermovir excipients list
DailyMed Link:letermovir at DailyMed
Recent Clinical Trials for letermovir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisN/A
Ohio State University Comprehensive Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 2

See all letermovir clinical trials

US Patents and Regulatory Information for letermovir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-001 Nov 8, 2017 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-001 Nov 8, 2017 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-002 Nov 8, 2017 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-002 Nov 8, 2017 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-001 Nov 8, 2017 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-002 Nov 8, 2017 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-001 Nov 8, 2017 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for letermovir

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1622880 C 2018 027 Romania   Get Started for $10 PRODUCT NAME: LETERMOVIR SAU SAREA SA, SOLVATUL SAU, SAU SOLVATUL SARII SALE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1245; DATE OF NATIONAL AUTHORISATION: 20180108; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1245; DATE OF FIRST AUTHORISATION IN EEA: 20180108
1622880 2018C/015 Belgium   Get Started for $10 PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU/1/17/1245 20180110
1622880 CR 2018 00026 Denmark   Get Started for $10 PRODUCT NAME: LETERMOVIR, OR ITS SALT, SOLVATE OR SOLVATE OF ITS SALT; REG. NO/DATE: EU/1/17/1245 20180110
1622880 2018/026 Ireland   Get Started for $10 PRODUCT NAME: LETERMOVIR, OR ITS SALT, SOLVATE, OR SOLVATE OF ITS SALT.; REGISTRATION NO/DATE: EU/1/17/1245 20180108
1622880 LUC00070 Luxembourg   Get Started for $10 PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU71/17/1245 20180110
1622880 28/2018 Austria   Get Started for $10 PRODUCT NAME: LETERMOVIR ODER DESSEN SALZ, SOLVAT ODER SOLVAT DES SALZES; NAT. REGISTRATION NO/DATE: EU/1/17/1245/001 - EU/1/17/1245/004 (MITTEILUNG) 20180110; FIRST REGISTRATION: EU EU/1/17/1245/001 - EU/1/17/1245/004 20180110
1622880 132018000000381 Italy   Get Started for $10 PRODUCT NAME: LETERMOVIR, O IL SUO SALE, SOLVATO O SOLVATO DEL SUO SALE(PREVYMIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1245/001-004, 20180110
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Boehringer Ingelheim
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.